Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Stopped early · Phase 2

Conditions studied: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes

In brief

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of T cell removal to prevent graft-versus-host disease in patients who are undergoing bone marrow transplantation from a donor.

Key facts

Study ID

NCT00005641

Run by

H. Lee Moffitt Cancer Center and Research Institute

Starts

1997-09-01

Expected to finish

2000-09-01

Last updated by the study team

2012-12-11

Who can join

Age: 15 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.